AURKB and cervical carcinoma: To investigate if there was similar sensitivity between LXY18 and AURKB catalytic inhibitors, we utilized the human cervical cancer cell line, Hela, and the lung adenocarcinoma cell line, Calu-6 (Fig 1A and 1C), both of which respond poorly to AURKB small molecule inhibitors.